Study Title
D5290C00004-A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)
Purpose
To determine if the study vaccine administered to healthy infants entering their first RSV season, in reducing lower respiratory tract infection due to confirmed RSV.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
CGIRB
IRB Number:
Trial Type:
Drug
Sponsor:
Astra Zenca
Contact Information: